• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺素用于无脑儿妊娠的处理

Prostaglandins for the management of anencephalic pregnancy.

作者信息

Thiery M, Parewijck W, Decoster J M

出版信息

Prostaglandins. 1981 Feb;21(2):207-15. doi: 10.1016/0090-6980(81)90138-6.

DOI:10.1016/0090-6980(81)90138-6
PMID:7221011
Abstract

In 17 women carrying an anencephalic fetus (3 or them dead) an attempt was made to terminate the pregnancy with either intravaginal suppositories containing 20 mg prostaglandin E2 each or serial intramuscular injections of 250 microgram of 15(S)-15-methyl-prostaglandin F2 alpha. The duration of pregnancy ranged from 18 to 39 weeks (mean: 28.5 weeks). Fifteen women expelled the complete uterine contents after a period ranging from 4:15 to 39:10 h:min (mean: 15:11 h:min) following the initiation of treatment. There were two failures, and in both of these cases labor started spontaneously after cessation of the prostaglandin treatment. No serious complications occurred. The PG treatment induced no changes in routine laboratory values and significant alterations in the mother's vital signs were uncommon. Even though intravaginal prostaglandin E2 and intramuscular 15-methyl-prostaglandin F2 alpha often produced gastro-intestinal side effects, there can be no doubt as to the unique utility of these compounds for the management of anencephalic pregnancies, whatever the duration of gestation and vital status of the fetus.

摘要

对17例怀有无脑儿胎儿的孕妇(其中3例胎儿已死亡)进行了妊娠终止尝试,分别采用了每枚含20毫克前列腺素E2的阴道栓剂,或连续肌肉注射250微克的15(S)-15-甲基前列腺素F2α。妊娠持续时间为18至39周(平均:28.5周)。15名妇女在开始治疗后的4小时15分钟至39小时10分钟(平均:15小时11分钟)内排出了全部子宫内容物。有2例失败,在这两例中,前列腺素治疗停止后均自发开始分娩。未发生严重并发症。前列腺素治疗未引起常规实验室值的变化,母亲生命体征的显著改变也不常见。尽管阴道用前列腺素E2和肌肉注射15-甲基前列腺素F2α常产生胃肠道副作用,但无论妊娠持续时间和胎儿生命状态如何,这些化合物在处理无脑儿妊娠方面的独特效用是毋庸置疑的。

相似文献

1
Prostaglandins for the management of anencephalic pregnancy.前列腺素用于无脑儿妊娠的处理
Prostaglandins. 1981 Feb;21(2):207-15. doi: 10.1016/0090-6980(81)90138-6.
2
Termination of molar pregnancy by intramuscular administration of 15(S)-15-methyl-prostaglandin F2 alpha.通过肌内注射15(S)-15-甲基前列腺素F2α终止葡萄胎妊娠。
Prostaglandins Med. 1980 May;4(5):333-9. doi: 10.1016/0161-4630(80)90007-5.
3
Comparison of two prostaglandins used to terminate midtrimester pregnancy.用于终止中期妊娠的两种前列腺素的比较。
South Med J. 1984 Jun;77(6):717-8, 721. doi: 10.1097/00007611-198406000-00013.
4
Prostaglandin F2 alpha for interrupting pregnancy, managing intrauterine death and molar pregnancy and inducing labor.前列腺素F2α用于终止妊娠、处理死胎及葡萄胎妊娠并引产。
Int J Gynaecol Obstet. 1980 Jan-Feb;17(4):362-7.
5
Termination of early gestation with (15S)-15-methyl prostaglandin F2 alpha methyl ester vaginal suppositories.
Contraception. 1981 Dec;24(6):617-30. doi: 10.1016/0010-7824(81)90013-5.
6
Missed abortion, hydatidiform mole and intra-uterine fetal death treated with 15-methyl-prostaglandin F 2-alpha.
S Afr Med J. 1980 Nov 29;58(22):878-80.
7
Termination of very early pregnancy by vaginal suppositories-(15S)-15-methyl prostaglandin F2 alpha methyl ester.
Contraception. 1981 Dec;24(6):603-15. doi: 10.1016/0010-7824(81)90012-3.
8
Second-trimester abortion by intramuscular 15-methyl-prostaglandin F2 alpha or intravaginal prostaglandin E2 suppositories: a randomized trial.
Obstet Gynecol. 1995 May;85(5 Pt 1):697-700. doi: 10.1016/0029-7844(95)00011-f.
9
Prostaglandin E2 vaginal suppositories in pregnancy with an anencephalic fetus.妊娠合并无脑儿使用前列腺素E2阴道栓剂。
Obstet Gynecol. 1980 Jun;55(6):758-60.
10
Pharmacotherapeutics of prostaglandin E2 and 15 (S) 15-methyl prostaglandin F2 alpha in chronic schistosomal bladder ulcer: a clinico-endoscopic study.前列腺素E2和15(S)-15-甲基前列腺素F2α在慢性血吸虫性膀胱溃疡中的药物治疗:一项临床内镜研究
Prostaglandins. 1982 Jul;24(1):97-104. doi: 10.1016/0090-6980(82)90181-2.